•             

Cart 0

Tumor Microenvironment and Cancer Immunity

The tumor microenvironment (TME) represents the intricate milieu surrounding a tumor, comprising various cellular and non-cellular components that intricately interact with cancer cells. This dynamic and multifaceted environment exerts a profound influence on tumor progression, metastasis, and response to therapy. The TME is a complex network of immune cells, fibroblasts, blood vessels, extracellular matrix components, and signaling molecules, collectively orchestrating a supportive or inhibitory landscape for the tumor.

Within the TME, specific protein markers play crucial roles in modulating tumor behavior and are often indicative of the immune response, angiogenesis, and extracellular matrix composition.

Some notable protein markers specific to the TME include:

PD-L1 (Programmed Death-Ligand 1): PD-L1 is expressed on the surface of tumor cells and immune cells within the TME. Its interaction with PD-1 on immune cells can suppress the immune response, facilitating immune evasion by the tumor.

TGF-β (Transforming Growth Factor-beta): TGF-β is a multifunctional cytokine in the TME that regulates processes such as cell proliferation, differentiation, and immune response. Its dysregulation contributes to the immunosuppressive nature of the TME.

VEGF (Vascular Endothelial Growth Factor): VEGF is a key protein involved in angiogenesis within the TME. It promotes the formation of new blood vessels, supporting tumor growth and providing a route for metastatic spread.

Granzyme B: Granzyme B is an enzyme released by cytotoxic T cells and natural killer cells within the TME. Its presence reflects the cytotoxic activity of the immune response against tumor cells.

Understanding the intricate interplay between these protein markers and the TME is crucial for developing targeted therapies that aim to manipulate the tumor microenvironment to enhance anti-tumor immune responses or disrupt supportive factors for tumor growth.

Download the "Tumor Microenvironment and Cancer Immunity" white paper:

DOWNLOAD WHITE PAPER
 

Anti-FN1 Antibody
Anti-FN1 Antibody

Anti-FN1 Antibody

AMAb91223
In Stock (10+)
3 665,0 kr
Anti-VIM Antibody
Anti-VIM Antibody

Anti-VIM Antibody

AMAb90516
In Stock (10+)
3 665,0 kr
Anti-ARG1 Antibody
Anti-ARG1 Antibody

Anti-ARG1 Antibody

AMAb90545
In Stock (10+)
4 311,0 kr
Anti-LAG3 Antibody
Anti-LAG3 Antibody

Anti-LAG3 Antibody

HPA013967
In Stock (10+)
4 311,0 kr
Anti-TOX Antibody
Anti-TOX Antibody

Anti-TOX Antibody

HPA018322
In Stock (10+)
4 311,0 kr
Anti-FOXP3 Antibody
Anti-FOXP3 Antibody

Anti-FOXP3 Antibody

HPA045943
In Stock (10+)
3 665,0 kr
Anti-CD248 Antibody
Anti-CD248 Antibody

Anti-CD248 Antibody

HPA051856
In Stock (10+)
4 570,0 kr
Anti-CD163 Antibody
Anti-CD163 Antibody

Anti-CD163 Antibody

HPA051974
In Stock (10+)
3 665,0 kr